^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RAD9A (RAD9 Checkpoint Clamp Component A)

    i
    Other names: RAD9A, RAD9 Checkpoint Clamp Component A, Cell Cycle Checkpoint Control Protein RAD9A, DNA Repair Exonuclease Rad9 Homolog A, HRAD9, RAD9, RAD9 Homolog A (S. Pombe), RAD9 (S. Pombe) Homolog, RAD9 Homolog A
    Associations

    News

    Trials
    3ms
    The 9-1-1 complex protects ssDNA gaps in BRCA2-deficient cancer. (PubMed, bioRxiv)
    We propose a model in which ssDNA gaps, when extended beyond a critical length, become inaccessible to TLS-mediated repair and are fully reliant on homologous recombination. These findings establish the 9-1-1 complex as key regulator of ssDNA gap stability and a promising therapeutic target in BRCA2-deficient cancers.
    Journal
    |
    BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • RAD9A (RAD9 Checkpoint Clamp Component A)
    4ms
    Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma. (PubMed, Adv Sci (Weinh))
    Delactylation of these proteins significantly hinders the formation of FEN1-RAD1-RAD9A-HUS1 complex, thereby leading to dysfunction of NHEJ and increasing the sensitivity of cancer cells to cisplatin. In summary, this work identifies LDHA lactylation as a critical mechanism for accelerating the progression of LUAD and reveals how this lactylation influenced cisplatin sensitivity of LUAD cells, which deepen the understanding of lactylation-mediated tumor progression and provide a potential new anticancer strategy.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • FEN1 (Flap Structure-Specific Endonuclease 1) • RAD9A (RAD9 Checkpoint Clamp Component A)
    |
    cisplatin
    7ms
    Proteomic Analysis of Hsp90β-selective Inhibitors Against Triple-negative Breast Cancer (TNBC) to Gain a Mechanistic Insight. (PubMed, Mol Cell Proteomics)
    The three example proteins selected exemplify a mechanistic explanation for inhibition of DNA-repair (RAD9A), cell cycle (CDK1), and translation (RPS9), shedding some light on some of the implications of Hsp90β inhibition as it pertains to TNBC. Therefore, previously unknown clients, Hsp90β interactors, or Hsp90β-regulated proteins could be determined using the results from this study.
    Journal
    |
    CDK1 (Cyclin-dependent kinase 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • RAD9A (RAD9 Checkpoint Clamp Component A)
    7ms
    Using machine learning to discover DNA metabolism biomarkers that direct prostate cancer treatment. (PubMed, Sci Rep)
    These genes not only serve as potential biomarkers for prognosis but also offer promising targets for personalized therapies. The integration of multi-omics data and advanced computational models provides new insights into the molecular underpinnings of PC and holds potential for improving treatment strategies.
    Journal
    |
    MSH6 (MutS homolog 6) • POLD1 (DNA Polymerase Delta 1) • POLD2 (DNA Polymerase Delta 2) • REV3L (REV3 Like DNA Directed Polymerase Zeta Catalytic Subunit) • RAD9A (RAD9 Checkpoint Clamp Component A)
    9ms
    Identification and Evaluation of Biomarkers for Diagnosis of chronic hepatitis B Using RNA-Seq. (PubMed, Virus Res)
    Based on multiple RNA-seq data of tissues and plasma exosomes, we identified PXN-AS1, RAD9A, SLC17A9 as diagnostic biomarkers for CHB detection. The model based on three biomarkers showed potential diagnostic value for detecting CHB. Additional validation with a larger sample size is essential to thoroughly assess the reliability of these three biomarkers and the model's performance.
    Journal
    |
    PXN (Paxillin) • SLC17A9 (Solute Carrier Family 17 Member 9) • RAD9A (RAD9 Checkpoint Clamp Component A)
    9ms
    Autophagy promotes the acquisition of genotoxic resistance in cancer cells in a paracrine manner via upregulation of PLK1-RAD9A axis. (PubMed, J Biochem)
    Together our data demonstrate that intra-tumor heterogeneity contributes to the malignant features of tumors through an autophagy-PLK-RAD9A axis that promotes intercellular communication via secretion. (180 words).
    Journal
    |
    PLK1 (Polo Like Kinase 1) • RAD9A (RAD9 Checkpoint Clamp Component A)
    10ms
    A gene signature associated with cellular senescence serves as an important prognostic indicator in hepatocellular carcinoma. (PubMed, Transl Cancer Res)
    This study established a prognostic model of HCC based on cellular senescence-related gene expression. Our findings may provide insights that can be used to develop novel potential targeted therapies.
    Journal • Gene Signature
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog) • CD8 (cluster of differentiation 8) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • MYBL2 (MYB Proto-Oncogene Like 2) • CDC25A (Cell Division Cycle 25A) • E2F5 (E2F Transcription Factor 5) • GADD45G (Growth Arrest And DNA Damage Inducible Gamma) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • RHEB (Ras Homolog, MTORC1 Binding) • RAD9A (RAD9 Checkpoint Clamp Component A)
    over1year
    Unveiling an anoikis-related risk model and the role of RAD9A in colon cancer. (PubMed, Int Immunopharmacol)
    Differences in survival time and the tumor immune microenvironment (TIME) were observed between two gene clusters associated with ARGs. In addition, a prognostic risk model was established and confirmed as an independent risk factor. Furthermore, our data indicated that RAD9A promoted tumorigenicityby activating AKT in colon cancer.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDC25C (Cell Division Cycle 25C) • SNAI1 (Snail Family Transcriptional Repressor 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • RAD9A (RAD9 Checkpoint Clamp Component A)
    over1year
    Discovery and validation of combined biomarkers for the diagnosis of esophageal intraepithelial neoplasia and esophageal squamous cell carcinoma. (PubMed, J Proteomics)
    Our findings suggest that combined detection of KDM2A, RAD9A, ECT2, CYHR1 and TONSL can be used as potential biomarkers for the early diagnosis of ESCC and precancerous lesion development prediction. SIGNIFICANCE: Candidate biomarkers including KDM2A, RAD9A, ECT2, CYHR1 and TONSL screened by integrating genomic and proteomic data from the esophagus can be used as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma and precancerous lesion development prediction.
    Journal
    |
    RAD9A (RAD9 Checkpoint Clamp Component A)
    over2years
    Construction and Validation of a Prognostic Model Based on Pyroptosisrelated Genes in Bladder Cancer. (PubMed, Comb Chem High Throughput Screen)
    This study presents the development and validation of a novel gene signature associated with pyroptosis, which holds the potential for predicting patient outcomes in BCa and providing insights into the immune microenvironment of BCa.
    Journal
    |
    ANXA1 (Annexin A1) • EHBP1 (EH Domain Binding Protein 1) • RAD9A (RAD9 Checkpoint Clamp Component A)
    over2years
    Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer. (PubMed, Cardiovasc Toxicol)
    Finally, we validated the expression level of immune-related genes in breast cancer patients-derived cardiomyocytes with doxorubicin-induced cardiotoxicity and found that the level of RAD9A, HSPA1B, GATA2, IGF2R, CD200, ERCC8, and BCL11A genes are consistently dysregulated. Our findings offered a basis for understanding the mechanism and pathogenesis of the cardiotoxicity caused by doxorubicin in breast cancer patients and predicted the interaction of immune-related potential biomarkers with doxorubicin.
    Journal • BRCA Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • BRCA (Breast cancer early onset) • BIRC3 (Baculoviral IAP repeat containing 3) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD200 (CD200 Molecule) • CD79A (CD79a Molecule) • GATA2 (GATA Binding Protein 2) • BTLA (B And T Lymphocyte Associated) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CPA3 (Carboxypeptidase A3) • FCRL1 (Fc Receptor Like 1) • LRP1 (LDL Receptor Related Protein 1) • MS4A1 (Membrane Spanning 4-Domains A1) • TCL1A (TCL1 Family AKT Coactivator A) • FCRLA (Fc Receptor Like A) • FCRLB (Fc Receptor Like B) • RAD9A (RAD9 Checkpoint Clamp Component A)
    |
    doxorubicin hydrochloride